trastuzumab,pertuzumab
roche
['phergain']
 this is not a km-curve, this is a km-line ( ) survival analysis of 86 pts from phergain trial who received only tp (chemo-free regimen by pet-guided de-escalation) 3yos: 100% only 1 event of idfs (locoregional recurrence) #asco23 
Medical Oncology Resident, European Institute of Oncology (@IEOufficiale), Milan